Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy
Pamela A. Frischmeyer‐GuerrerioLaboratory of Allergic Diseases, Food Allergy Research Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MdMadhan MasilamaniDepartment of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NYWenjuan GuClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, NCI Campus, Frederick, MdErica BrittainBiostatistics Research Branch, Division of Clinical Research, National Institutes of Health, Bethesda, MdRobert A. WoodDepartment of Pediatrics, Division of Allergy and Immunology, Johns Hopkins University School of Medicine, Baltimore, MdJennifer KimDepartment of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NYKari C. NadeauDepartments of Medicine and Pediatrics, Sean N. Parker Center for Allergy and Asthma Research, Stanford School of Medicine, Stanford, CalifKirsi M. JärvinenDepartment of Pediatrics, Division of Allergy and Immunology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NYAlexander GrishinDepartment of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NYRobert LindbladEMMES Corporation, Rockville, MdHugh A. SampsonDepartment of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: [email protected]
2017en
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba